Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update

J Clin Oncol. 2023 Jun 20;41(18):3423-3425. doi: 10.1200/JCO.23.00638. Epub 2023 May 17.

Abstract

ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. See the Appendix for disclaimers and other important information (Appendix 1 and Appendix 2, online only).

Publication types

  • Practice Guideline

MeSH terms

  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / genetics
  • Erb-b2 Receptor Tyrosine Kinases / genetics
  • Erb-b2 Receptor Tyrosine Kinases / metabolism
  • Estrogen Receptor alpha* / genetics
  • Female
  • Humans
  • Mutation

Substances

  • Erb-b2 Receptor Tyrosine Kinases
  • ERBB2 protein, human
  • ESR1 protein, human
  • Estrogen Receptor alpha